Content Stream
DBV Submits Viaskin Peanut Treatment for FDA Biologics License
DBV Technologies today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Viaskin Peanut for the treatment of peanut allergy in children four to 11 years of age. Viaskin Peanut is the Company’s lead product candidate, which is based on epicutaneous immunotherapy (EPIT), a proprietary technology platform that delivers biologically active compounds to the immune system
Egg Replacer
Forum: Food and Cooking
Following Hurricane Michael, People in the Florida Panhandle Are in Desperate Need of Allergy-Friendly Food
Hurricane Michael left historical devastation on the Florida Panhandle. Many affected people are in dire need of help. You can help get safe food to the affected areas.